PT - JOURNAL ARTICLE AU - Nakashima, Kei AU - Ishida, Masayuki AU - Matsui, Hiroyuki AU - Yoshida, Chihiro AU - Nagai, Tatsuya AU - Shiraga, Minoru AU - Nakaoka, Hiroshi AU - Otsuka, Yoshihito AU - Nakagama, Yu AU - Kaku, Natsuko AU - Nitahara, Yuko AU - Kido, Yasutoshi AU - Hirota, Yoshio TI - Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study AID - 10.1101/2022.06.23.22276536 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.23.22276536 4099 - http://medrxiv.org/content/early/2022/06/26/2022.06.23.22276536.short 4100 - http://medrxiv.org/content/early/2022/06/26/2022.06.23.22276536.full AB - Introduction This study assessed the immunogenicity and safety of BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment using two immunoassays. Methods: We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients with chronic diseases; all participants were fully vaccinated with the BNT162b2 vaccine. Blood samples were collected before the first and second vaccinations and 4 ± 1 weeks after the second vaccination. Anti-acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein S1 subunit receptor-binding domain antibody titers were measured using the Architect SARS-CoV-2 IgG II Quant (Abbott Laboratory) and Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics).Results Fifty-five lung cancer patients and 38 non-cancer patients were included in the immunogenicity analysis. Lung cancer patients showed significant increase in the geometric mean antibody titer, which was significantly lower than that in the non-cancer patients after the first (30 vs. 121 AU/mL, p<0.001 on Architect; 4.0 vs 1.2 U/mL, p<0.001, on Elecsys) and second vaccinations (1632 vs. 3472 AU/mL, p=0.005, on Architect; 213 vs 573 A/mL, p=0.002, on Elecsys). The adjusted odds ratio (OR) for seroprotection was significantly lower in the lung cancer patients. Analysis of the anticancer treatment types showed that the adjusted OR for seroprotection was significantly lower in lung cancer patients receiving cytotoxic agents. Lung cancer patients showed no increase in the number of adverse reactions.Conclusions BNT162b2 vaccination in lung cancer patients undergoing anticancer treatment significantly increased antibody titers and showed acceptable safety. However, the immunogenicity in these patients could be inadequate compared with that in non-cancer patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a Grant-in-Aid for the Investigation of the Promotion of Health Labor Administration (Research Project for the Promotion of Policies for Emerging and Re-emerging Infectious Diseases and Immunization; Principal Investigator: Yoshio Hirota; Grant Number: 20HA2001), Japan Society for the Promotion of Science KAKENHI [Grant Number: 22K15927 (Yu Nakagama)] and Japan Agency for Medical Research and Development (AMED) [Grant Numbers: JP20he1122001 (Yasutoshi Kido) and JP20jk0110021 (Yu Nakagama)]. We received support from Osaka City University's "Special Reserves" fund for COVID-19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hakata Clinic Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCI,confidence interval;COVID-19,coronavirus disease;GMT,geometric mean antibody titer;ICIs,immune-checkpoint inhibitors;OR,odds ratio;sP,seroprotection rate;TKIs;tyrosine kinase inhibitors.